If you missed the latest live-stream from the International Progressive MS Alliance on new treatments for progressive MS, don’t worry you can catch up now!

New, effective treatments are urgently needed for people with progressive MS. Hear from leading MS experts about the current state of treatments for progressive MS, active clinical trials that may provide new solutions, and research efforts to develop breakthrough treatments to ultimately end MS progression.

Catch-up now!

Watch the webcast below and keep scrolling to read more about the host and expert panel. Click the settings toggle in the bottom right corner to watch the video with English, Spanish, Italian, Arabic, French or Czech subtitles.

Webcast Panel 



Kathy Smith is a pharmacologist and worked in the pharmaceutical industry in Research, Clinical Development and Strategy for over 25 years. She has worked in a professional capacity with the National MS Society’s Research (USA) on key strategic research efforts and has also provided expertise to the International Progressive MS Alliance.  Kathy is also a passionate advocate and fundraiser for the National MS Society.  She was diagnosed with MS in 2004.



Professor Robert Fox, MD is the Chair of the Scientific Steering Committee of the International Progressive MS Alliance.  He serves as Staff Neurologist at the Mellen Center for Multiple Sclerosis, Vice-Chair for Research at the Neurological Institute, Cleveland Clinic, and Professor of Neurology at Cleveland Clinic Lerner College of Medicine. Dr Fox’s research interests focus on clinical trials in multiple sclerosis, innovative MRI techniques to evaluate tissue recovery after injury and the effects of MS treatments, as well as MS patient decision-making and tolerance to risk. He has published more than 200 peer-reviewed papers, book chapters, and books.


Don Mahad, MD, PhD is Senior Clinical Lecturer and Honorary Consultant Neurologist at the University of Edinburgh, UK. His research is focused on bioenergetic changes in progressive multiple sclerosis patients as well as experimental disease modes, particularly the role of mitochondria. Furthermore, his research group explores the potential consequences of mitochondrial dysfunction and energy failure for the clinical presentation of progressive MS. Findings from his work are driving the discovery of potential neuroprotective drugs for treating progressive MS.  He is a recipient of an Alliance Challenges in Progressive MS Award and he has authored numerous papers.




Clare Walton, PhD, is Head of Research at the MS Society in the UK where she looks after their research funding progamme and strategic projects related to MS prevention, research capacity building and symptom management research. Clare’s field of expertise is in neural stem cells and brain repair and has spent the last decade working in non-profit organisations across a range of neurological conditions.



About the International Progressive MS Alliance 

The International Progressive MS Alliance is a first-of-its-kind global research network aimed at accelerating the development of new, effective treatments for progressive MS. We are rallying the world through an unprecedented collaboration of MS organisations, researchers, healthcare professionals, pharmaceutical companies, trusts, foundations, donors and people affected by MS. Our promise is more than hope; it is progress.

Catch-up on the previous Alliance webcasts here